Jaguar Health Names Principal Investigators For Clinical Trial To Support Full Approval Of Canalevia-CA1 For Treatment Of Chemotherapy-Induced Diarrhea In Dogs
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health has announced the principal investigators for a clinical trial aimed at gaining full FDA approval for Canalevia-CA1, a treatment for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, which is currently conditionally approved by the FDA, is the first and only treatment for this condition to receive any type of approval.
July 26, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's announcement of principal investigators for a clinical trial of Canalevia-CA1 could potentially lead to full FDA approval, which would likely have a positive impact on the company's stock.
The announcement of principal investigators for a clinical trial is a significant step towards full FDA approval. If Canalevia-CA1 receives full approval, it would be the only fully approved treatment for chemotherapy-induced diarrhea in dogs, which could significantly boost Jaguar Health's market position and stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100